NICE Issues Draft Guidance on Astellas’ Xtandi and Janssen’s Zytiga for Prostate Cancer Treatment

NICE Issues Draft Guidance on Astellas’ Xtandi and Janssen’s Zytiga for Prostate Cancer Treatment
NICE issued its final draft guidance recommending enzalutamide (Xtandi, by Astellas Pharma) for prostate cancer (PC) patients who have already tried first-line treatments with no success, for those who have none to a few symptoms and for those who have not been recommended chemotherapy. According to a press release, the Appraisal Committee decided that enzalutamide is

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *